INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year’s BioProcess International Conference and Exhibition in Boston. S-DUAL™ is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces risks associated with chemistry, manufacturing and control (CMC), and thus ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability. DEVELOPICK™ is a rapid developability assessment platform that systematically screens molecules at an early development stage to identify candidates with the
The post Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022 appeared first on Pharma Mirror Magazine.
